Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question
Copyright policy )Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question
Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics.
- University of Florida United States
- University of Illinois at Chicago United States
Clinical Trials as Topic, Genotype, Racial Groups, Anticoagulants, Pharmacogenetics, Vitamin K Epoxide Reductases, Humans, Aryl Hydrocarbon Hydroxylases, Warfarin, Cytochrome P-450 CYP2C9
Clinical Trials as Topic, Genotype, Racial Groups, Anticoagulants, Pharmacogenetics, Vitamin K Epoxide Reductases, Humans, Aryl Hydrocarbon Hydroxylases, Warfarin, Cytochrome P-450 CYP2C9
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).25 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!